2022 Speakers

Richard Klein

Director, Expanded Access Programs and Policy

GE2P2 Global Foundation

Andrew McFadyen

Executive Director

The Isaac Foundation

Fiona Smythe

Chief Executive Officer

MedaSystems

Tamy Kim

Director for Regulatory Affairs and Policy Oncology Center for Excellence (OCE)

FDA

Cath Lawrence

Rare Disease Franchise Lead

Bionical Emas

Tom Watson

COO

Bionical Emas

Gwen Petersen

Patient Advocate

I AM ALS

Sandrine Fontaine

Head of CMO office Management and Oversight Office of the Chief Medical Officer

GSK

Sarah Misenko

Senior Manager, Office of CMO, Oncology

GSK

Donna Cowan

Associate Director Expanded Access Programs and Registry

Stealth BioTherapeutics

Karen Frascello

Director, Global Medical Affairs, Early Access

Alnylam Pharmaceuticals

Marjorie Zettler

Director of Clinical Science

Regor Pharmaceuticals

Kathleen Long

Director, Medical Affairs Operations

Alkermes, inc.

Christian Valencia

Medical Director, Global Medical Affairs Oncology

EMD Serono

Helen Kellar-Wood

Head, Pre-Approval Access Operations, Global Development Operations

Bristol Myers Squibb

Jean Godin

Global Head of Humanitarian & Managed Access Programs and Medical Governance

Sanofi Genzyme

Mari Mitrani

Chief Science Officer

Organicell

Daniel O’Connor

Medical Assessor

MHRA

Magali Taiel

Chief Medical Officer

Gensight-Biologics

Paula Singer

Senior Manager, Global Medical Affairs, Early Access

Alnylam Pharmaceuticals

Stephanie Petrone

Consultant

Navigate Clinical

Rachel Harrison

Associate Director, Early Access Programs

Apellis Pharmaceuticals

Jeffrey Waldron

Managing Director

Sherborn Consulting Group

Sara Radenovic

Associate Director, Managed Access Programs

GSK

Annmarie Galli

Head, Global Medical Affairs Research and Compassionate Use/ Managed Access Programs

GSK

Lisa Kearns

Researcher, Division of Medical Ethics

NYU Grossman School of Medicine

Tobias Polak

Director Real-World Data

myTomorrows